# Regulatory Hurdles for Humanoid Healthcare: US (FDA) vs. EU (MDR)

## General Challenges for Both Regions:

• **Novelty and Precedent**: Humanoid caregivers represent a novel category requiring immense complexity in establishing new pathways. This includes the need for potential pilot programs, extensive stakeholder engagement, and even legislative changes. Regulators will need to establish clear pathways and potentially adapt existing frameworks through unprecedented collaboration between multiple agencies and international bodies.

• **Safety and Efficacy**: Demonstrating that the humanoid is safe for interaction with vulnerable populations and effective in its caregiving tasks is paramount. This includes mechanical safety, software reliability, and preventing unintended harm, specifically: - **Cybersecurity Risks**: Humanoids represent potential targets when connected to healthcare systems, requiring robust protection against malicious attacks that could compromise patient safety or data integrity. - **Risk Management**: Rigorous processes such as FMEA (Failure Modes & Effects Analysis) and Fault Tree Analysis must be implemented to identify and mitigate potential failure scenarios. - **Usability & Human Factors**: Critical assessment of how humanoids interact with diverse user groups (e.g., elderly, cognitively impaired, physically disabled) for both safety and efficacy, ensuring accessibility and appropriate response to varied user capabilities.

• **Human-Robot Interaction (HRI)**: Special attention is needed for how the robot interacts with people, especially in an autonomous or semi-autonomous capacity. This includes aspects like communication, physical contact, and emotional impact. Extensive psychological and sociological studies are required to quantify and regulate the emotional impact on patients, caregivers, and healthcare staff.

• **Ethical Considerations**: Beyond regulation, ethical discussions around autonomy, accountability, potential for dependency, and the role of robots in personal care will be crucial. This significantly expanded area includes: - **Data Bias**: The risk of AI algorithms perpetuating biases present in training data, potentially leading to

discriminatory care delivery or unequal treatment outcomes. - **Accountability Chain**: The complex question of legal responsibility in case of errors, involving manufacturer liability, hospital responsibility, clinician oversight, and AI developer accountability. - **Informed Consent**: The challenge of obtaining truly informed consent for care delivered by autonomous or semi-autonomous systems, particularly when patients may not fully understand the technology's capabilities and limitations.

• **Post-Market Surveillance**: Continuous monitoring of the device once it's on the market to detect any unforeseen issues, adverse events, or performance degradation. This requires proactive elements including trending adverse events, regular safety updates, and Post-Market Clinical Follow-up (PMCF) studies to ensure ongoing safety and effectiveness throughout the device lifecycle.

## United States (FDA - Food and Drug Administration):

### 1. Medical Device Classification:

• **SaMD (Software as a Medical Device)**: The software driving the humanoid's caregiving functions (e.g., monitoring, reminding, assisting) will almost certainly be classified as SaMD, requiring its own comprehensive regulatory review with specific documentation and validation requirements.

• **Hardware Classification**: The physical robot itself will be classified as a medical device based on its intended use (e.g., monitoring vital signs, assisting with mobility, dispensing medication). The intended use drives classification, and any diagnostic, treatment, or significant monitoring function will push it to higher classes (Class II or III), requiring more rigorous review (510(k) premarket notification or PMA premarket approval).

• **Combination Products**: Humanoids dispensing medication may be classified as "combination products" (device + drug), adding significant regulatory complexity requiring coordination between CDRH (Center for Devices and Radiological Health) and CDER (Center for Drug Evaluation and Research), potentially extending approval timelines and costs.

### 2. FDA Medical Device Regulations:

• **21 CFR Part 820 (Quality System Regulation)**: Manufacturers must establish and maintain a quality system that covers design, production, and distribution of medical devices.

• **Premarket Notification (510(k)) or PMA**: For truly novel, high-risk humanoids, the PMA (Premarket Approval) pathway is far more likely than 510(k) due to the difficulty of demonstrating "substantial equivalence" to existing devices. The PMA pathway is significantly longer, costlier, and more rigorous, often requiring extensive clinical trials and comprehensive safety and effectiveness data.

### 3. Standards:

• **ISO 13485**: While not directly an FDA regulation, compliance with this international standard for medical device quality management systems is highly recommended and often a de facto requirement for FDA clearance. Non-compliance requires strong scientific and regulatory justification.

• **IEC 60601 Series**: Applicable for electrical medical equipment, this series covers general requirements for basic safety and essential performance. Recognition by FDA does not guarantee acceptance; non-compliance requires robust justification.

• **IEC 80601-2-78**: This specific standard focuses on "Medical robots for rehabilitation, assessment, compensation or alleviation of an impairment" – highly relevant for a caregiving humanoid.

• **ANSI/AAMI Standards**: Various American National Standards Institute/Association for the Advancement of Medical Instrumentation standards may apply depending on specific functionalities.

## European Union (MDR - Medical Device Regulation):

**Important Note**: Medical devices are regulated under the Medical Device Regulation (MDR) (EU 2017/745), not by the European Medicines Agency (EMA), which primarily deals with medicines.

## 1. MDR (Medical Device Regulation) (EU 2017/745):

This is the overarching regulation for medical devices in the EU.

- **CE Marking**: All medical devices placed on the EU market must bear a CE Mark, indicating conformity with the MDR.

- **Classification Rules**: The MDR has detailed classification rules (Class I, IIa, IIb, III) based on risk and invasiveness. A humanoid caregiver with advanced functions would likely fall into Class IIa, IIb, or III.

- **Notified Body**: For Class IIa, IIb, and III devices, involvement of a Notified Body is critical and mandatory for conformity assessment and CE Marking. This represents a significant bottleneck and cost factor, as Notified Bodies have limited capacity and charge substantial fees for their services.

- **General Safety and Performance Requirements (GSPR)**: Devices must meet comprehensive GSPRs outlined in Annex I of the MDR.

- **Clinical Evaluation**: Demonstrating clinical safety and performance through a rigorous clinical evaluation process.

- **Technical Documentation**: Comprehensive documentation covering design, manufacturing, risk management, and post-market surveillance.

- **Post-Market Surveillance (PMS) and PMCF**: Stringent MDR requirements for ongoing clinical data collection throughout the device's lifecycle, including systematic collection and analysis of post-market clinical data.

- **Person Responsible for Regulatory Compliance (PRRC)**: Mandatory role for manufacturers under MDR, requiring specific qualifications including a degree in law, medicine, pharmacy, engineering, or other relevant scientific discipline, plus one year of regulatory affairs experience.

## 2. SaMD (Software as a Medical Device):

The MDR explicitly includes software as a medical device and outlines its specific classification rules and requirements.

### 3. Standards:

• **ISO 13485**: Essential for demonstrating compliance with the MDR's quality management system requirements.

• **EN IEC 60601 Series**: Harmonized European versions of the IEC 60601 standards for electrical medical equipment.

• **EN IEC 80601-2-78**: The European harmonized version of the medical robot safety standard.

• **Other Harmonized Standards**: Various other EN (European Norm) standards will apply for specific aspects like usability, cybersecurity, and biocompatibility (if relevant).

## Privacy and Security Considerations (US HIPAA/HITECH vs. EU GDPR):

Both regions have stringent data privacy laws that are critical for humanoid caregivers, as they will likely collect sensitive personal health information (PHI).

### United States:

**1. HIPAA (Health Insurance Portability and Accountability Act) & HITECH Act (Health Information Technology for Economic and Clinical Health Act):**

• **Protected Health Information (PHI)**: Any individually identifiable health information collected, stored, transmitted, or used by the humanoid (e.g., vital signs, medication adherence, activity levels, verbal interactions about health) would be considered PHI.

• **Covered Entities & Business Associates**: If the humanoid is part of a healthcare provider's system or if the manufacturer/developer acts as a service provider handling PHI on behalf of a covered entity, they would need to be HIPAA compliant (as a business associate).

• **Business Associate Agreement (BAA)**: Mandatory requirement for a BAA between a Covered Entity and any Business Associate handling PHI, establishing specific

obligations and liability frameworks.

- **Security Rule**: Requires administrative, physical, and technical safeguards to protect electronic PHI (ePHI). This includes encryption, access controls, audit trails, and data integrity measures.

- **Privacy Rule**: Governs the use and disclosure of PHI, requiring patient consent for many uses and disclosures, and providing patients with rights over their health information.

- **Breach Notification Rule**: Mandates reporting of breaches of unsecured PHI with serious implications including substantial costs, reputational damage, and specific timelines for notification (60 days to HHS, immediate notification to affected individuals for breaches affecting 500+ individuals).

## European Union:

**1. GDPR (General Data Protection Regulation) (EU 2016/679):**

- **Personal Data & Special Categories of Data**: Health data is explicitly defined as a "special category" of personal data, requiring higher levels of protection.

- **Lawfulness of Processing**: Processing of health data usually requires explicit consent from the individual, though other potential legal bases exist (e.g., legitimate interest, vital interests), with consent often preferred for health data due to its sensitive nature.

- **Data Protection Officer (DPO)**: Certain companies must appoint a DPO, particularly those processing large amounts of special category data or conducting systematic monitoring.

- **Data Protection by Design and Default**: Privacy and security measures must be built into the system from the ground up, not added as an afterthought.

- **Data Protection Impact Assessments (DPIA)**: Likely required due to the high-risk nature of processing sensitive health data with new technology.

- **Technical and Organizational Measures**: Strong security measures (encryption, pseudonymization, access controls, regular testing) are mandatory to protect personal data.

• **Data Subject Rights**: Individuals have extensive rights, including access, rectification, erasure, and restriction of processing.

• **Right to Be Forgotten/Erasure**: Presents technical challenges for fully erasing data and significant impact on continuously learning AI models, which may need to be retrained after data deletion.

• **Cross-Border Data Transfers**: Strict rules apply if data is transferred outside the EU/EEA, with historical and ongoing complexities including the invalidation of Privacy Shield and current reliance on Standard Contractual Clauses and adequacy decisions.

## Regional Approaches to AI Regulation: Diverging Philosophies and Implementation Strategies

The regulatory landscape for artificial intelligence technologies, including those integrated into medical devices like humanoid caregivers, varies significantly across major jurisdictions, reflecting fundamentally different philosophical approaches to innovation and risk management.

### European Union (EU AI Act):

The European Union has adopted a comprehensive, risk-based regulatory framework through the EU AI Act, which categorizes AI systems into four risk tiers:

• **Unacceptable Risk (Prohibited)**: AI systems that pose unacceptable risks to safety, livelihoods, and rights are banned outright. The implications of "unacceptable risk" classifications may significantly impact the future evolution of humanoid AI, particularly in areas involving social scoring or real-time biometric identification.

• **High Risk (Strict Requirements)**: AI applications used in healthcare, critical infrastructure, and law enforcement require rigorous conformity assessments, CE marking, and ongoing monitoring.

• **Limited Risk (Transparency Obligations)**: AI systems that interact with humans must clearly disclose their artificial nature.

• **Minimal Risk (No Specific Obligations)**: Low-risk AI applications with minimal regulatory requirements.

**Key Requirements for High-Risk AI Systems:** • Detailed documentation and technical specifications • Implementation of human oversight mechanisms • Regular audits and compliance assessments • Algorithmic transparency and bias testing • Explainability requirements for AI-driven decision-making processes

For humanoid healthcare devices, this means additional layers of compliance beyond traditional medical device regulations under the MDR.

## United States (Sector-Specific Approach):

The United States has pursued a more sector-specific and innovation-friendly approach, relying primarily on existing regulatory frameworks adapted for AI applications rather than creating overarching AI-specific legislation. However, "innovation-friendly" also means less certainty and a more fragmented regulatory landscape compared to the EU.

**FDA Guidance on AI/ML-Based Medical Devices:** • Predetermined change control plans for continuous learning algorithms • Software as a Medical Device (SaMD) classification and requirements • Focus on post-market surveillance and real-world performance monitoring • Emphasis on manufacturer responsibility for self-regulation

**Key Differences from EU Approach:** • No comprehensive risk categorization system • Greater flexibility in implementation • Prioritizes rapid innovation and market deployment • Less prescriptive regulatory requirements

## Global Compliance Challenges:

This regulatory divergence creates significant compliance challenges for global manufacturers of AI-enabled medical devices:

• **Dual Compliance Requirements**: Companies must navigate both EU's prescriptive requirements and US's more flexible regulatory environment.

• **System Variations**: Different versions of AI systems may be needed to meet varying transparency, explainability, and human oversight requirements across jurisdictions. This implies potentially different product versions (not just paperwork) for different markets, significantly impacting R&D, manufacturing, and maintenance strategies.

- **Cost Implications**: Compliance costs extend beyond mere regulatory fees to include development of jurisdiction-specific features and documentation.

- **Innovation Impact**: The pace of innovation and global deployment strategies for advanced healthcare robotics may be affected by these regulatory differences.

- **Market Access**: Timing of product launches may vary significantly between regions due to different approval processes and requirements.

## Conclusion

Navigating the regulatory landscape for humanoid healthcare is an endeavor of immense complexity, requiring a deeply integrated and forward-thinking compliance strategy. While this document effectively outlines the key regulatory frameworks and common challenges in both the US and EU, success hinges on a profound appreciation for the nuances of medical device classification, the rigorous demands of clinical evidence generation for novel technologies, and the ever-evolving nature of AI and data privacy regulations. Proactive engagement with regulatory bodies, coupled with a robust quality management system and a realistic timeline for extensive clinical validation, will be paramount in bringing these transformative caregiving solutions safely and effectively to market.

## Disclaimer

The information provided in this document is for general informational purposes only and does not constitute legal, medical, or regulatory advice. Regulatory pathways for novel technologies, particularly those involving artificial intelligence, robotics, and healthcare, are complex and subject to change. Readers should consult with qualified legal, regulatory, and medical professionals to address specific situations and ensure compliance with all applicable laws and regulations in their respective jurisdictions. The projections, timelines, and financial estimates presented are illustrative and based on assumptions that may not materialize.

Basel, 4th Sept 2025 Andrew Squire, *Founder* HumanoidHealthcare.org

Slide 1: Conceptual Regulatory and Pilot Timeline Plans for Europe




Slide 2: To include US and EU, then a Dual Track Regulatory Strategy is Required

Slide 3: The success of Humanoid Healthcare in resolving the Human Caregiver crisis demands substantial time and investment. To achieve this, a powerful consortium of sponsors and strategic partnerships, potentially bolstered by national governmental health services, is imperative. While the regulatory hurdles are formidable, we **must** overcome them. This is the only path to mitigate the immense legal liability stemming from the high risk misuse of general-purpose Home Humanoids as caregivers, making this initiative an absolute necessity.